Predicting liver repair in hepatitis B after treatment
Part of Digestive system, Infections clinical trials.
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a liver biopsy at least 1 year after starting antiviral treatment for hepatitis B.
- You had a liver biopsy, a liver stiffness measurement, or a specific blood test (APRI) before starting antiviral therapy.
- You do not have advanced cirrhosis complications like fluid in the belly, confusion, or bleeding from veins in the esophagus.
- You do not have liver cancer or a history of liver transplant.
- You do not have other liver diseases like hepatitis C, HIV, alcoholic liver disease, or autoimmune hepatitis.
- You are not pregnant or breastfeeding, and have no other serious organ diseases or active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study looks at whether measuring spleen stiffness and simple blood tests can predict if the liver will recover in people with decompensated cirrhosis. It may help doctors know which patients can improve with treatment.
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Hear when a new Chronic Hepatitis B Virus (HBV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.